A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2020-10-02
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the progression free survival (PFS), based on
investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic
renal cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Agensys, Inc. Astellas Pharma Global Development, Inc.